Articles related to Pharmacy Benefit Management

< back to service

Selling Prescription Drugs Directly to Patients? OIG Flags Anti-Kickback Pitfalls with TrumpRx and Other DTC Programs

[02/13/26]

Federal PBM Reform Is Here: Unpacking Key Provisions of the Landmark Legislation

[02/05/26]

Michigan Sues PBMs for Alleged Anticompetitive Conduct Impacting Independent Pharmacies

[05/21/25]

FTC Releases Second Interim Staff Report on Pharmacy Benefit Managers

[01/29/25]

Pressure on PBMs Intensifies as FTC Targets Top PBMs Over Insulin Rebates

[09/30/24]

U.S. Supreme Court Issues Ruling Rejecting Challenge to Mifepristone Access

[06/18/24]

Federal Court of Appeals Panel Issues Ruling in Litigation Challenging FDA Approval of Mifepristone

[08/31/23]

Proposed CMS Rule Targets PBM Price Transparency for Medicaid Managed Care Organizations

[06/23/23]

A Look Back at the Office of Prescription Drug Promotion Enforcement in 2022 and Lessons for 2023

[03/29/23]

No Surprises Act Enforcement Begins

[02/20/23]

FTC Launches Inquiry into Pharmacy Benefit Managers: Is This Time Different?

[06/15/22]

PREP Act Eligibility Expanded for Pharmacists, Pharmacy Technicians and Interns Administering COVID-19 Therapeutics

[10/01/21]

HHS Advisory Opinion: Drug Manufacturers Must Offer 340B Program Discounts to Contract Pharmacies

[02/25/21]

Open the Floodgates: U.S. Supreme Court Decides ERISA Does Not Preempt Arkansas State Law Regulating PBMs

[12/23/20]

OIG Finalizes Controversial Rule Updating AKS Discount Safe Harbor Applicable to Prescription Drug Rebates

[12/21/20]

New CMS Most Favored Nation Drug Pricing Rule Could Negatively Impact the Bottom Lines of Hospitals, Physician Practices

[12/04/20]

New DEA Pharmacist’s Manual: Top Five Changes Pharmacies Need to Know

[11/11/20]

Pharmacists’ Expanded Authority to Administer Childhood Vaccines: What to Know

[10/06/20]

D.C. Circuit Upholds 340B Drug Reimbursement Cuts: Is This the End of the Road?

[08/07/20]

Assessing the Impact of the New Drug Pricing Executive Orders

[07/31/20]

Eligible Outpatient Facilities of 340B Hospitals Can Now Bypass Registration Delays

[06/05/20]

Hospitals Fear Pandemic May Threaten Their Eligibility to Participate in the 340B Drug Program

[05/29/20]

PREP Act Immunity for Pharmacists Ordering COVID-19 Tests: New HHS OGC Advisory Opinion Addresses Conflicting State Laws

[05/21/20]

A COVID-19 340B Update: OPA Updates Its GPO Prohibition Guidance and Other Outstanding 340B Program Issues

[03/25/20]

USP Publishes Guidance on Conserving PPE in Sterile Compounding and Compounding Hand-Sanitizer During COVID-19 Pandemic

[03/23/20]

COVID-19 Testing Update: Legal Considerations for Drive-Through Collection Sites, Diagnostic Testing Sites and Diagnostic Test Development

[03/20/20]

Informational Bulletin from CMS Addresses Best Practices to Avoid 340B Duplicate Discounts

[01/17/20]

Attention Nonresident Alaska Pharmacies, Distributors and 3PLs: State Implements New Nonresident Licensing Classifications and Prescription Requirements for Controlled Substances

[11/01/19]

Proposed CMS Hospital Survey Could Support CMS’s Efforts to Reduce 340B Drug Reimbursement

[10/07/19]

CMS Continues 340B Payment Cuts in 2020 OPPS Proposed Rule Yet Acknowledges Potential for Future Reversal

[08/02/19]

CMS Updates Preclusion List Requirements for Medicare Advantage and Part D

[05/10/19]

D.C. Court Decides Medicare 340B Program Payment Reduction Lawsuit Remedy: Spoiler Alert – The End Is Not Here

[05/08/19]

340B Moving Forward: Legislative and Executive Branch 340B Priorities for 2019-2020

[04/19/19]

The 340B Crystal Ball: New Clarity on 340B Prices and the Program’s Future

[04/05/19]

Claims Denials Start April 1: What You Should Know About CMS’s New Preclusion List

[02/15/19]

Digital Medicine: OIG Approves Arrangement to Provide Smartphones to Patients

[02/15/19]

Discount Disruption: PBM Rebate Protection May Be Removed, New Safe Harbors Combat Increasing Drug Costs

[02/01/19]

FDA Clarifies Position on CBD After Passage of 2018 Farm Bill

[01/18/19]

Impact Analysis: Federal Court Blocks 2018 Cuts to 340B Drug Discount Program Payments

[01/11/19]

CMS Proposes to Require Manufacturers to Disclose Drug Prices in TV Ads

[11/21/18]

CMS Proposes Major Change to Medicare Part B Drug Payment System Introducing International Pricing Index Model

[11/09/18]

FDA Issues New Draft MOU for 503A Compounders Governing Cross-Border Dispensing and Comments Related to CGMP Compliance for Outsourcing Facilities

[11/02/18]

Newly Enacted Opioid Law: How Does It Impact Providers?

[10/26/18]

DOJ Approves Merger Between Cigna and Express Scripts, Paving the Way for Increased Vertical Integration Between Payers and PBMs

[10/04/18]

CMS Allows Medicare Advantage Plans to Implement Step Therapy for Part B Drugs – Will It Really Lower Drug Costs or Simply Increase Administrative Burdens?

[09/19/18]

340B Program OPPS Payment Reductions and Legislative Limitation Proposals: What’s Smoke and What’s Fire?

[07/27/18]

Wisconsin Court Analyzes Relationship Between 340B and Wisconsin Medicaid Requirements in Important Overpayment Case

[07/13/18]

CMS Removes Compliance Training Requirements for Downstream Providers Under Medicare Advantage and Part D

[07/05/18]

CMS Announces New Opioid Safety Measures for Part D Plan Sponsors: What Is Really Going On?

[05/23/18]

The Wave of PBM and Insurer Integration Continues as Cigna and Express Scripts Announce a Merger of Their Own

[03/16/18]

DOJ Announces New Prescription Interdiction & Litigation Task Force to Combat Prescription Opioid Crisis

[03/05/18]

Medicare 340B Payment Cuts Go Live as of January 1. What’s Next?

[01/05/18]

Federal Judge Denies Hospitals’ Motion to Enjoin Imminent 340B Program Payment Cuts

[12/30/17]

OIG Rescission of 2006 Advisory Opinion: An Important Compliance Reminder

[12/11/17]

OIG Approves Pharmaceutical Manufacturer’s Replacement Program for Spoiled Biologics

[09/06/17]

340B in 2017 and Beyond: What Covered Entities and Contract Pharmacies Need to Know

[08/11/17]

New Indiana Law Imposes a Seven-Day Limit on Opioid Prescriptions

[06/21/17]

Prescriber Enrollment Requirements for Part D Prescriptions: Enforcement to Begin in Early 2017

[04/19/17]

340B “Mega-Guidance” Withdrawn – Next Steps Unclear

[02/01/17]

Pharmacy Lawsuit Challenges Government Investigation After Relying on Purported Prior Telephone Assurance from Regulators

[01/25/17]

Pharmacy Fraud and Abuse: Operationalizing the New OIG Final Rule in an Integrated Care Environment

[01/04/17]

Efforts to Enhance Prescription Drug Pricing Transparency Gaining Traction: Implications for Pharmacy Stakeholders

[11/30/16]

New Wisconsin Pain Clinic Certification Requirement Enacted

[09/01/16]

OIG Issues Favorable Advisory Opinion on Prescription Drug Discount Program

[08/11/16]

Medicare Part D Fraud and Specialty Drugs Highlighted in OIG’s 2016 Work Plan

[12/09/15]

FDA Again Delays Drug Product Tracing Obligations for Dispensers (Including Pharmacies and Physician Offices) to March 1, 2016

[11/02/15]

340B Program Omnibus Guidance: A Deeper Dive

[09/03/15]

Breaking: HRSA Releases Preliminary Version of Proposed 340B Omnibus Guidance

[08/27/15]

FDA Delays Enforcement of Dispensers’ Drug Product Tracing Obligations Until November 1, 2015

[07/01/15]

340B Program House Subcommittee Testimony: Overview and Insights

[03/30/15]

OIG Studies Medicare’s Oversight of Hospital Pharmaceutical Compounding Practices in Wake of 2012 Meningitis Outbreak

[02/23/15]

OIG Provides More Exclusion Guidance Through Recent Advisory Opinion

[02/19/15]

OIG Warns That Manufacturer Safeguards May Not Prevent Copayment Coupon Use for Part D Drugs

[10/21/14]

OIG Scrutinizes Specialty Pharmacy Arrangement in Unfavorable Advisory Opinion

[08/26/14]

A Balancing Act: Pending Legislation Seeks to Improve Prescription Drug Access While Curbing Abuse

[08/04/14]

OIG Updates Guidance on Prescription Drug Patient Assistance Programs

[06/25/14]

Implications of the U.S. District Court Opinion Vacating the 340B Program’s “Orphan Drug” Final Rule and Regulations

[05/29/14]

OIG Proposes Substantial Changes to Its Civil Monetary Penalty Rules

[05/21/14]

Potential Prescription Drug Audit Areas Highlighted in the OIG’s Fiscal Year 2014 Work Plan

[02/18/14]

Proposed New Law Creates “Safe Pharmacies” Aimed to Fight Controlled Substance Abuse and Includes Other Anti-Fraud Measures

[02/05/14]

President Signs Compounding Pharmacy Bill – First Related FDA Guidance Published

[12/01/13]

The Drug Quality and Security Act: Implications of the Proposed New Law for Compounding Pharmacies and the Pharmaceutical Supply Chain

[11/26/13]

OIG Study Offers Insight to Pharmacies Regarding How to Evaluate Physicians’ Prescribing Habits

[11/13/13]

Sunshine Act Compliance Begins: CMS Provides Related Payment Tracking Apps, Q&As and Other Resources

[08/09/13]

HRSA Issues 340B Program Orphan Drug Final Rule and Regulations

[07/24/13]

OIG Issues Updated Guidance for Exclusions

[05/10/13]

OIG Issues Updated Self-Disclosure Protocol

[04/22/13]

HRSA Extends 340B GPO Exclusion Guidance Compliance Deadline from April 7, 2013 to August 7, 2013

[04/08/13]

Final Sunshine Rule Requires Reporting of Physician Ownership in GPOs and Health Products Manufacturers

[03/13/13]

CMS Publishes the Final Physician Payment Sunshine Rule

[02/20/13]

Opportunities for Pharmacies and Long-Term Care Facilities in the new DEA Proposed Rule for Controlled Substance Disposal, but what about Hospitals?

[12/28/12]

Proposed Drug Shortage Bill Threatens 340B Drug Discounts for Injectables

[12/13/12]

OIG Advisory Opinion 12-14: OIG Approves Retail Rewards Program That Includes Purchases at In-Store Pharmacies

[10/19/12]

Potential Prescription Drug Audit Areas Highlighted in the OIG’s Fiscal Year 2013 Work Plan

[10/05/12]

OIG Reminds Pharmacies of Proper Schedule II Billing Practices

[09/28/12]

Pharmacies and Drug Distributors Take Note: DEA Revokes Registration of Two CVS Pharmacies

[09/14/12]

Cardinal Health Reaches Settlement with DEA

[05/16/12]

OIG Study Perceives Questionable Part D Billing by Retail Pharmacies

[05/14/12]

Pharmacies Beware, Wholesalers May Start Closely Scrutinizing Your Purchasing Habits of Controlled Substances

[03/02/12]

Possible Rural Health Clinic Deeming Authority on the Horizon – Comments Requested

[11/08/11]